Creative Biogene Liver Cancer Pathway Offers Advanced Support for Drug Discovery Projects

New York – May 30th, 2019 – In recent years, hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. It is also the third most common cause of cancer-related mortality. In addition, the incidence of HCC has increased in many countries over the past decade.

The biggest risk factors associated with the development of HCC are hepatitis B and C virus infections. Hepatitis infection is thought to increase the risk of developing HCC by a factor of 20 and is the leading cause of more than 80% of HCC cases. Other major risk factors include excessive alcohol consumption, nonalcoholic steatohepatitis, exposure to environmental toxins such as aflatoxin B, cirrhosis, hemochromatosis, diabetes and obesity. Creative Biogene, as an innovative biotechnology products and services provider, recently releases its liver cancer pathway to support the process of the drug discovery projects.

Hepatocarcinogenesis is a complex and multi-step process that combines epigenetic and genetic alterations. In recent decades, many efforts have been made to identify key molecules involved in the development and progression of HCC. A variety of signaling pathways that affect angiogenesis, cell proliferation, invasion and metastasis are deregulated in HCC. Among them, the most frequently reported pathways involve growth factors such as insulin-like growth factor (IGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF).

IGF signaling is important for the regulation of growth and development and has been shown to involve the pathogenesis of several malignancies, including HCC. Alterations in this pathway include allelic loss of the IGFR2 receptor and overexpression of the IGF2 ligand. Furthermore, selective blockade of IGF signaling has an anti-tumor effect in an experimental model of HCC. Various components of the HGF/MET pathway have been suggested to contribute to HCC progression. EGFR also shows the presence of signaling, which is overexpressed in mRNA and protein levels.

Down-regulation of EGF in cirrhotic tissues appears to influence the development of HCC, as indicated by the genetic markers that predict the prognosis of surgically resected HCC patients. In addition, high serum VEGF levels are associated with aggressive cancer behavior and poor prognosis. Finally, based on evidence, the importance of this system in HCC progression and acquired resistance to VEGF treatment is increasing in interest in anti-fibroblast growth factor (FGF) therapy in HCC.

‘In recent years, great progress has been made in better understanding the molecular mechanisms of carcinogenic processes. A number of cellular signaling pathways have been identified that are involved in the pathogenesis of tumors, leading to the identification of new molecular targets for therapeutic development. Various strategies for these approaches have been explored and have shown varying degrees of success in the clinic.’ said Marcia Graby, the marketing director of Creative Biogene, she also claimed, ‘Other new strategies are being studied and hope that more effective treatments may be forthcoming. Creative Biogene will be always dedicated to offering powerful support in this process.’

About Creative Biogene

Creative Biogene, as a top-of-its-kind company who holds a leading position and is committed to accelerating the development of human science through biotechnology, offering innovative technologies, products, unique tools and services for research discoveries and product development. With more than 10 years of experience and in-house experts, Creative Biogene has become a well-recognized industry leader to support researchers worldwide.

Media Contact
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Phone: 6316197922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States